Pfizer Begins Testing of Pill to Treat COVID

Sign up to stay connected

Get the top stories of the day around the DMV.

• WIN Daily Start your weekdays right with the most recent stories from the Washington Informer website. Once a day Monday-Friday.
• JPMorgan Chase Money Talks Presented with JPMorgan Chase, this financial education series is dedicated to bridging the racial wealth gap. Let's embark on a journey of healthy financial conversations together. Bi-Monthly.
• Our House D.C. Dive deep into our monthly exploration of the challenges and rewards of Black homeownership. Monthly.
• Deals & Offers Exclusive perks, updates, and events from The Washington Informer partners just for you.

Pfizer says it has begun a large-scale study of a pill to prevent COVID-19 infections among people who have been exposed.

The drugmaker announced Monday that the mid-to-late-stage study will test the pill in up to 2,660 healthy participants 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection, Reuters reported.

Pfizer also has started another study of the pill in non-hospitalized, symptomatic adult patients, Reuters reported.

Gilead Sciences Inc’s intravenous drug remdesivir is currently the only approved antiviral treatment for COVID-19 in the U.S.